Bengaluru, Feb. 5 -- This Small-cap Pharma Stock, engaged in manufacturing affordable generic tablets, capsules, and injectables for infections, pain, and allergies across India and global markets, hit a 5 percent upper circuit after the company reported December quarterly results with 566.61 percent Revenue Growth and 759.07 percent Profit growth in Q3 FY26.

With a market capitalization of Rs. 1,770.35 crores, the shares of Shukra Pharmaceuticals Limited hit a 5 percent upper circuit of Rs. 40.43 per share on Thursday, up from its previous closing price of Rs. 38.51 per share.

Q3 FY26 Result

Coming into the quarterly results of Shukra Pharmaceuticals Limited, the company's consolidated revenue from operations increased by 269.85 perce...